A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...
The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...
The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results